Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Medical Crossfire®: How Can Liquid Biopsies Drive Precision Care in Frontline NSCLC?

Release Date: January 31, 2020
Expiration Date: January 31, 2021
Media: Internet - based

Activity Overview

Consensus guidelines recommend universal reflex testing for oncogenic mutations in non-small cell lung cancer (NSCLC), and there are now at least 8 targetable mutations in lung cancer with more than 20 approved treatments. Optimizing testing methods to ensure patients receive targeted treatment as quickly as possible is crucial, and navigating tissue collection and testing continually evolves with emerging data regarding these options. In the frontline setting of NSCLC, clinicians must have a level of comfort with the use of short-turnaround liquid biopsy, either in combination with tissue biopsy or as the only available test when patients cannot undergo tissue biopsy. Liquid biopsy also has an important role in monitoring changes in mutational characteristics over time and guiding treatment in later lines of therapy. In this online Medical Crossfire® program, the expert panel will review the latest data regarding mutational analysis, targeted therapy, and the challenges and advantages associated with liquid biopsy testing techniques. Through panel discussion and case-based analyses, standards of care and emerging options to improve outcomes in NSCLC will be placed into clinical context to help you optimize care for your patients.

Benefits of Participating

  • Hear the latest strategies used by experts to apply liquid biopsy in the care of patients with NSCLC
  • Learn when liquid biopsy should be used in practice and how this test is evolving
  • Benefit from expert discussion on how to overcome challenges in applying liquid biopsy techniques to benefit your patients

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Target Audience

This educational activity is intended for medical oncologists, pathologists, and fellows who treat patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung cancer will be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Analyze the results of clinical studies to evaluate the strengths and limitations of this technology versus conventional tissue biopsy.
  • Examine the scientific rationale for use of liquid biopsy technology to inform frontline clinical decision making in the management of lung cancer.
  • Contrast available and emerging testing technology, including sensitivity, specificity, and relevance in the frontline management of NSCLC.
  • Summarize clinical evidence regarding specific testing modalities to individualize targeted treatment of NSCLC in the frontline setting.

Faculty, Staff, and Planners’ Disclosures


Benjamin P. Levy
Benjamin P. Levy, MD
Associate Professor, Johns Hopkins School of Medicine
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC

Disclosures: Consultant: AstraZeneca; Celgene Corporation; Eli Lilly and Company; Genentech; Merck & Co, Ltd; Takeda Pharmaceutical Company Limited.

Joshua Bauml
Joshua Bauml, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Disclosures: Grant Research Support: Amgen; AstraZeneca; Bayer; Carevive Systems, Inc; Incyte Corporation; Janssen Pharmaceuticals; Merck & Co, Ltd; Novartis; Takeda Pharmaceutical Company Limited; Consultant: AstraZeneca, Ayala, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Genentech, Guardant Health, Inc; Janssen Pharmaceuticals; Merck & Co, Ltd; Regeneron Pharmaceuticals; Takeda Pharmaceutical Company Limited.

Zofia Piotrowska
Zofia Piotrowska, MD, MHS
Instructor of Medicine, Harvard Medical School
Assistant in Medicine, Massachusetts General Hospital
Boston, MA

Disclosures: Grant Research Support: AstraZeneca, Novartis, Spectrum, Takeda Pharmaceutical Company Limited, Tesaro; Consultant: AstraZeneca, Eli Lilly, Incyte Corporation, Medtronic, Genentech.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or the company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By